Kampala — Uganda has approved Lenacapavir, a twice-yearly injectable HIV prevention medicine developed by Gilead Sciences, in a move health officials say could accelerate the country’s drive to sharply cut new infections and meet global targets to end AIDS as a public health threat by the end
Twenty-five years ago, South Africans battled for ARVs to keep people alive. Now the focus has shifted to medicines that can prevent HIV altogether. Health Beat looks how the story has evolvedSouth Africa has successfully registered twice-a-year anti-HIV jab, lenacapavir.This World
Malawi yesterday launched Lenacapavir, a twice-yearly injectable HIV prevention medicine amid reflections on whether the country can sustainably finance emerging technologies in the face of waning donor support.Pharmacy and Medicines Regulatory Authority (PMRA) and National Aids Commission
You can now be vaccinated against HIV – but that does not mean you can be reckless, warns the Department of Healthscientist-hiv-vaccinationA scientist holds a batch of tests. Image: CDC on UnsplashFrom March 2026, people at high risk of contracting HIV will be able to visit
THE Medicines Control Authority of Zimbabwe (MCAZ) has approved a new long-acting medicine, Lenacapavir, to help prevent HIV infection.Lenacapavir, is used for pre-exposure prophylaxis (PrEP) in adults and adolescents who weigh at least 35kg.It is for people who are HIV-negative but
Minister of Health, Dr Jane Ruth Aceng, has welcomed a landmark global deal that will dramatically slash the cost of the HIV prevention drug, lenacapavir, making it affordable for millions in low- and middle-income countries.The announcement was made on W
USAID road localisation show. USAID had embarked on funding locally lead initiatives across Uganda. PHOTO URNKampala, Uganda | USAID has been present in Uganda for over sixty years. It has funded development in agriculture, education
KAMPALA, Uganda – June 29, 2025 – The Uganda AIDS Commission today announced the successful conclusion of research on Lenacapavir, a groundbreaking six-monthly injectable pre-exposure prophylaxis (PrEP), that has demonstrated 100% effectiveness in preventing
The future may be getting brighter in terms of reducing the threat of the human immunodeficiency virus (HIV), infectious disease experts told Newsweek.With new treatments and maybe even a vaccine on the horizon, 2
